Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.23%
1,103.85
-2.51
-0.23%
1,106.361,105.681,109.291,104.25
SIXC
Communications
SIXC
Communications
SIXC
+0.61%
614.02
+3.73
+0.61%
610.29610.29613.92610.29
SIXE
Energy
SIXE
Energy
SIXE
+0.04%
1,211.71
+0.49
+0.04%
1,211.221,211.011,212.241,209.79
SIXI
Industrials
SIXI
Industrials
SIXI
+0.14%
1,753.08
+2.37
+0.14%
1,750.711,753.101,757.861,753.10
SIXM
Financials
SIXM
Financials
SIXM
+0.80%
633.22
+5.05
+0.80%
628.17629.38633.75629.38
SIXR
Staples
SIXR
Staples
SIXR
+0.42%
858.18
+3.61
+0.42%
854.57855.71858.11855.71
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.28%
217.47
+0.60
+0.28%
216.87216.87217.75216.87
SIXT
Technology
SIXT
Technology
SIXT
+0.29%
3,572.27
+10.33
+0.29%
3,561.943,571.443,574.033,562.15
SIXU
Utilities
SIXU
Utilities
SIXU
+0.01%
903.41
+0.100
+0.01%
903.31903.26904.33903.26
SIXV
Health care
SIXV
Health care
SIXV
-0.06%
1,480.62
-0.92
-0.06%
1,481.541,482.481,483.831,480.62
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.46%
2,410.95
+11.00
+0.46%
2,399.952,404.452,412.722,404.45
CRSP:NASDAQ
Crispr Therapeutics AG
$50.95
-3.41%
(-1.80) 1D
May 14, 9:40:16 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRSP...
Open
$52.90
High
$53.49
Low
$50.89
Mkt. cap
4.91B
Avg. vol.
1.70M
Volume
43.61K
52-wk high
$78.48
52-wk low
$34.87
EPS
-$6.21
Beta
1.27
Shares outstanding
96.45M
No. of employees
393
News stories
From sources across the web
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Switzerland
SectorBiotechnology
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
892.00K
889.00K
864.00K
1.46M
Cost of goods sold
115.05M
116.02M
137.23M
114.52M
Cost of revenue
115.05M
116.02M
137.23M
114.52M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18.92M
16.93M
18.40M
17.18M
Operating expense
18.92M
16.93M
18.40M
17.18M
Total operating expenses
133.96M
132.95M
155.63M
131.71M
Operating income
-133.07M
-132.06M
-154.76M
-130.25M
Other non operating income
22.07M
26.24M
24.76M
8.16M
EBT including unusual items
-207.26M
-105.82M
-130.00M
-122.09M
EBT excluding unusual items
-111.00M
-105.82M
-130.00M
-122.09M
Income tax expense
1.29M
619.00K
614.00K
839.00K
Effective tax rate
-0.62%
-0.58%
-0.47%
-0.69%
Other operating expenses
-
-
-
-
Net income
-208.55M
-106.44M
-130.61M
-122.93M
Net profit margin
-23,379.93%
-11,973.12%
-15,117.25%
-8,431.48%
Earnings per share
-1.29
-1.17
-1.37
-1.28
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-128.42M
-127.63M
-149.10M
-125.93M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more